These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20960887)

  • 41. Serum C-reactive protein as a marker for wellness assessment.
    Kao PC; Shiesh SC; Wu TJ
    Ann Clin Lab Sci; 2006; 36(2):163-9. PubMed ID: 16682512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cardiovascular risk factors--where do these come from? Interview by Nicola von Lutterotti].
    Assmann G
    Dtsch Med Wochenschr; 2005 Oct; Suppl 1():33-4. PubMed ID: 16379234
    [No Abstract]   [Full Text] [Related]  

  • 43. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.
    Bijl M; Bootsma H; Van Der Geld Y; Limburg PC; Kallenberg CG; Van Rijswijk MH
    Ann Rheum Dis; 2004 Jul; 63(7):831-5. PubMed ID: 15194579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pentraxin-3 as a marker of both the presence and the severity of metabolic syndrome.
    Canpolat U; Turak O; Tok D; Çağlı K; Aydoğdu S
    Med Princ Pract; 2014; 23(4):390. PubMed ID: 24504179
    [No Abstract]   [Full Text] [Related]  

  • 45. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.
    Savchenko A; Imamura M; Ohashi R; Jiang S; Kawasaki T; Hasegawa G; Emura I; Iwanari H; Sagara M; Tanaka T; Hamakubo T; Kodama T; Naito M
    J Pathol; 2008 May; 215(1):48-55. PubMed ID: 18220316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated C-reactive protein in atherosclerosis--chicken or egg?
    Schunkert H; Samani NJ
    N Engl J Med; 2008 Oct; 359(18):1953-5. PubMed ID: 18971498
    [No Abstract]   [Full Text] [Related]  

  • 47. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.
    Smith SC; Anderson JL; Cannon RO; Fadl YY; Koenig W; Libby P; Lipshultz SE; Mensah GA; Ridker PM; Rosenson R; ;
    Circulation; 2004 Dec; 110(25):e550-3. PubMed ID: 15611380
    [No Abstract]   [Full Text] [Related]  

  • 48. Pentraxin 3 and C-reactive protein in severe meningococcal disease.
    Sprong T; Peri G; Neeleman C; Mantovani A; Signorini S; van der Meer JW; van Deuren M
    Shock; 2009 Jan; 31(1):28-32. PubMed ID: 18650775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inflammation and hypertension: new clinical information on pentraxin-3.
    Yano Y; Hatakeyama K
    Anadolu Kardiyol Derg; 2012 Jun; 12(4):305-6. PubMed ID: 22466362
    [No Abstract]   [Full Text] [Related]  

  • 50. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain.
    Brügger-Andersen T; Pönitz V; Kontny F; Staines H; Grundt H; Sagara M; Nilsen DW
    Thromb Haemost; 2009 Sep; 102(3):555-63. PubMed ID: 19718477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pentraxin 3 levels in women with fibromyalgia.
    Skare TL; Plawiak AC; Veronese G; Paiva ES; Messias-Reason I; Nisihara R
    Clin Exp Rheumatol; 2015; 33(1 Suppl 88):S142. PubMed ID: 25664655
    [No Abstract]   [Full Text] [Related]  

  • 52. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CRP and cardiovascular disease: linked by complement?
    Hack CE
    Neth J Med; 2002 Aug; 60(7):297-8. PubMed ID: 12430579
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to Agilli and Aydin.
    Karppelin M; Syrjänen J
    J Infect; 2015 May; 70(5):547-9. PubMed ID: 25596513
    [No Abstract]   [Full Text] [Related]  

  • 55. Pentraxin 3 as a new biomarker of diastolic dysfunction.
    Liu Q; Tu T; Bai Z; Zhou S
    Int J Cardiol; 2011 Oct; 152(1):106-7. PubMed ID: 21855152
    [No Abstract]   [Full Text] [Related]  

  • 56. Significance of pentraxin-3 in patients with juvenile scleroderma.
    Adrovic A; Sahin S; Barut K; Durmus S; Uzun H; Kasapcopur O
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):221-222. PubMed ID: 28664833
    [No Abstract]   [Full Text] [Related]  

  • 57. Pentraxin-3 levels in systemic lupus erythematosus: Association with cumulative damage but not with disease activity.
    Skare TL; Nisihara R; Ramos GP; Utiyama SR; Messias-Reason I
    Joint Bone Spine; 2015 Dec; 82(6):466-7. PubMed ID: 26184527
    [No Abstract]   [Full Text] [Related]  

  • 58. Higher pentraxin-3 level in patients with metabolic syndrome.
    Balta S; Demırkol S; Unlu M; Cakar M; Arslan Z; Akhan M
    Med Princ Pract; 2013; 22(5):513-4. PubMed ID: 23899711
    [No Abstract]   [Full Text] [Related]  

  • 59. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.
    Veletic I; Manshouri T; Newberry KJ; Garnett J; Verstovsek S; Estrov Z
    Br J Haematol; 2019 Apr; 185(2):382-386. PubMed ID: 30074241
    [No Abstract]   [Full Text] [Related]  

  • 60. Association of long pentraxin-3 with pulmonary hypertension and primary graft dysfunction in lung transplant recipients.
    Diamond JM; Ramphal K; Porteous MK; Cantu E; Christie JD; Kawut SM;
    J Heart Lung Transplant; 2018 Jun; 37(6):792-794. PubMed ID: 29370970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.